| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -10,527 | -11,148 |
| Depreciation | 978 | 640 |
| Amortization of intangible assets | 8,132 | 5,421 |
| Amortization of premium/discount on investments | 0 | 0 |
| Amortization of debt discount and debt issuance costs | 2,507 | 1,664 |
| Amortization of operating right-of-use assets | 386 | 246 |
| Deferred income tax expense (benefit) | 0 | 0 |
| Stock-based compensation | 17,094 | 9,451 |
| Change in fair value of contingent value rights | 0 | 0 |
| Trade accounts receivable | 13,336 | 12,633 |
| Prepaid expenses and other current assets | 3,350 | -1,803 |
| Inventory | 15,275 | 11,190 |
| Accounts payable | 1,629 | -367 |
| Other accrued liabilities | -398 | -3,230 |
| Accrued trade discounts and rebates | 20,375 | 8,445 |
| Accrued returns reserve | 134 | 700 |
| Operating lease liabilities | -1,154 | -742 |
| Other | 1,388 | 1,091 |
| Net cash provided by (used in) operating activities | 8,583 | -9,849 |
| Capital expenditures | -363 | -292 |
| Purchases of investments | 0 | 0 |
| Sales and maturities of investments | 0 | 0 |
| Net cash provided by (used in) investing activities | -363 | -292 |
| Proceeds from debt refinancing | 0 | 0 |
| Payment of debt discount | 0 | 0 |
| Proceeds from issuance of employee stock purchase plan shares | 830 | 830 |
| Proceeds from exercise of stock options | 10,994 | 5,833 |
| Proceeds from issuance of warrants | 9,167 | - |
| Repurchase of common stock withheld for taxes | 9,336 | 8,858 |
| Net cash provided by (used in) financing activities | 11,655 | -2,195 |
| Net cash provided by (used in) in cash, cash equivalents and restricted cash | 19,875 | -12,336 |
| Cash and cash equivalents at beginning of period | 75,744 | - |
| Cash and cash equivalents at end of period | 95,619 | - |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)